In transcatheter embolization and occlusion, a minimally invasive procedure used in interventional radiology, a synthetic embolus is inserted into a blood vessel through a tiny catheter to obstruct blood flow to tumors or other specific areas of the body. Liquid-suspended particles like gelatin-impregnated acrylic sphere polymer and polyvinyl alcohol (PVA) are injected into the bloodstream to block small blood arteries. Coils, which come in various sizes and shapes, are eternal embolic devices coated with chemotherapeutic medications that cause cytotoxicity to attack the tumor and obstruct blood supply.
The Global Transcatheter Embolization and Occlusion Devices Market was valued at US$ 3,198.3 Million in 2022 and is anticipated to reach US$ 6,306.2 Million by the end of 2030 with a CAGR of 8.9% from 2023 to 2030.
These procedures also aid in removing improper connections between the arterial and venous systems and preventing or controlling abnormal bleeding. Moreover, they aid in the management of aneurysms. Unlike open and invasive surgical techniques, transcatheter embolization is particularly effective at controlling bleeding without being invasive. The use of TEO devices is another area where this technology is becoming more widely adopted. Non-coil products like embolization particles and liquid embolic aid minimally invasive surgery. Therefore, using these devices helps prevent issues like catheter entrapment, inaccurate installation, and balloon deflation brought on by coiling. Surgeons are increasingly moving towards non-coil devices to take advantage of these benefits, which is expected to increase revenue for TEO devices.
Transcatheter embolization is a useful therapeutic option for several gynecological and obstetric problems. It is feasible to skip surgery with minimally invasive transcatheter embolization procedures, which minimize mortality and morbidity while preserving a patient’s possibility for future conception. Under the direction of knowledgeable interventional radiologists and with the help of essential technological support, transcatheter embolization is utilized to cure an array of ulcerations in the female pelvis, like ectopic pregnancy, arteriovenous malformation, and advanced-stage cancer. It is also used to treat pelvic congestion syndrome and uterine fibroids symptoms after women have undergone the requisite examination. Embolization to treat uterine polyps has recorded 85% and higher global success rates for women.
Transcatheter Embolization and Occlusion Devices Market Amid COVID-19 Pandemic
Due to the COVID-19 outbreak, Transcatheter Embolization and Occlusion Devices have become increasingly important. In an effort to contain the spread of the disease, government-imposed lockdowns restricted movement and limited regular check-ups. Elective procedures were postponed, but patients infected with the virus were given priority. This has resulted in reduced demand for Transcatheter Embolization and Occlusion Devices. However, as the number of COVID-19 cases decreases and vaccination rates increase, there will likely be a surge in demand for these devices.
The healthcare sector is slowly returning to normal as patient visits resume, production facilities reactivate, and lockdown restrictions are lifted. The market for transcatheter embolization and occlusion devices was significantly affected by COVID-19, but there has been a sharp rise in sales of medical products in response to the pandemic. The medical industry continues to require more medical supplies due to the increase in COVID-19 cases worldwide, which has had an impact on every market. Despite stricter regulations, the medical supply and catheter sectors were able to meet demands for medical procedures. The pandemic resulted in a greater need for respiratory support equipment and life-supporting machines, but producers of this safety gear were able to keep up with demand.
It is projected that the demand for Transcatheter Embolization and Occlusion Devices will increase during the projection period. Despite the impact of the pandemic, the industry’s overall growth remains strong.
Increasing Prevalence of cardiovascular disorders respiratory disorders, and Cancer, the growing geriatric population, the surge in the need for treatment, patient awareness, technological advancements & increased healthcare expenditure to Boost the Transcatheter Embolization and Occlusion Devices Market
The demand for transcatheter embolization and occlusion devices is projected to rise due to several key factors in the healthcare landscape. These factors include an increasing incidence of cancer, respiratory illnesses, and cardiovascular diseases, a growing aging population, a higher demand for medical treatments, greater patient awareness, advancements in technology, and increased healthcare spending over the forecast period.
Transcatheter embolization and occlusion (TEO) is a minimally invasive treatment method. It involves the insertion of a synthetic embolus into a blood vessel via a catheter to reduce blood flow to a tumor or other targeted areas of the body. The market for these devices is expanding due to the rising demand for minimally invasive surgeries (MISs), a higher prevalence of specific diseases, technological innovations in more efficient systems, a shift from traditional clipping methods to coiling, and increased adoption of Transcatheter Embolization and Occlusion devices.
The use of transcatheter has seen significant growth in recent years, particularly with the transition from clipping to coiling and increased acceptance of transcatheter embolization and occlusion techniques. This growth is further boosted using minimally invasive procedures and the introduction of non-coil products like liquid embolic and embolization particles. The global increase in the prevalence of chronic diseases is another significant factor contributing to the expansion of the transcatheter embolization and occlusion market.
One of the primary drivers for the market is the aging global population. With improvements in healthcare infrastructure and available resources, people are living longer, and the average lifespan has increased. According to UN projections, by 2022, there will be over 727 million people aged 65 and older worldwide, with this elderly population expected to double in the next three decades to over 1.5 billion individuals. As the senior population grows, so will the demand for Transcatheter Embolization and Occlusion Devices.
Additionally, the market is expected to experience growth due to the increased introduction of new products and commercialization partnerships between major manufacturers and other businesses. For instance, Abbott’s Amplatzer steerable delivery sheath received CE mark and Health Canada certification. This innovative sheath is designed specifically for noninvasive left atrial appendage (LAA) occlusion procedures. Such developments are anticipated to drive the market for Transcatheter Embolization and Occlusion Devices further.
North America to spearhead the Transcatheter Embolization and Occlusion Devices Market.
The market in North America is propelled by the region’s highly developed healthcare system, rising provider awareness about transcatheter embolization and occlusion devices, and ongoing advancements in these technologies. In 2022, North America and Europe collectively represented the majority of revenue. Some of the factors driving the need for TEO devices in these areas include the presence of a modern well-defined regulatory framework, healthcare infrastructure, and skilled healthcare personnel to perform the operations. Throughout the predicted period, it is expected that both regions will continue to dominate.
North America is leading the transcatheter embolization and occlusion devices market due to the increasing prevalence of various chronic diseases. Due to this industry in North America is investing more and more in this sector. Moreover, the regulatory climate in North America is improving. Pharmaceutical businesses are finding it simpler to launch new drugs and products since regulatory agencies are creating clearer policies and procedures for the clearance of these therapies. The increasing elderly population in the country is one of the causes that is boosting the market. Increasing investments in R&D by the leading companies to develop new and advanced technologies are driving the market in the North America region. The markets in North America are being supported by rising patient awareness of the therapies, goods, and services available in the market for the treatment of different ailments including liver cancer, kidney cancer, venous blood clots, etc. Well-established infrastructure and medical services support the expansion of the local Transcatheter Embolization and Occlusion Devices market.
Companies operating in the Transcatheter Embolization and Occlusion Devices market include BTG plc, Boston Scientific Corporation, Medtronic plc, Penumbra, Inc., Cook Medical, Edwards Lifesciences Corporation, Merit Medical Systems, Johnson & Johnson Services, Inc., Pfizer, Inc., Stryker Corporation, Terumo Corporation, Sirtex Medical Limited, and Abbott Laboratories. These companies play a significant role in the development and distribution of devices used in minimally invasive procedures to treat vascular conditions.
In this industry, collaboration and expansion strategies are common. Firms often partner to exchange resources and expertise to accelerate the development of new treatments. Through such partnerships, companies can leverage each other’s skills to create innovative therapies. Additionally, they expand their market presence by entering new regions and markets with growth potential. This approach allows them to attract new customers, increase revenue, and acquire new technology through acquisitions or collaborations. Companies also invest in cost-effective product development to stay competitive and grow. Expanding product portfolios and incorporating new technologies are crucial steps for business expansion in this field.
These strategies ensure that companies in the Transcatheter Embolization and Occlusion Devices market continue to advance medical treatments and reach a wider patient population.